ReviewFrontiers in immunology2022
Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Intelligent structure prediction and visualization analysis of non-coding RNA in osteosarcoma research.Frontiers in oncology · 2024Pooled it
- Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives.Frontiers in immunology · 2024Pooled it
- Bone niche-driven antitumor immune failure in osteosarcoma: Mechanisms and therapeutic implications (Review).Oncology letters · 2026Review
- The Osteosarcoma Tumor Microenvironment: From Cellular Interactions to Advanced Preclinical Models.Cancers · 2026Review
- Genomic landscape and tumor immune microenvironment of osteosarcoma: Bridging mechanistic insights to precision therapeutics.Bone reports · 2026Review
- Phototherapy-responsive nanoplatform with hydrogel delivery potentiates immunotherapy and inhibits lung metastasis in osteosarcoma via synergistic glycolysis inhibition and vascular normalization.Journal of nanobiotechnology · 2026Article
- Article
- Single-cell transcriptomics reveals glycolytic heterogeneity and identifies STC2 as a key regulator of metabolic reprogramming in osteosarcoma.Molecular and cellular biochemistry · 2026Article
- Oncolytic virus with an immune stimulatory payload for osteosarcoma therapy.Cancer immunology, immunotherapy : CII · 2026Article
- Integrative single-cell and bulk analyses reveal ATF4-associated immune suppression and WNT/β-catenin signaling in osteosarcoma.Biology direct · 2026Article
- Immune modulatory oncolytic virus for osteosarcoma therapy.Research square · 2026Article
- A conceptual blueprint for "turning cold to hot" in Osteosarcoma: from TME stratification hypotheses to adaptive therapeutic prospects.Cell communication and signaling : CCS · 2026Review
- Dual-Responsive Micelles Co-delivering All-Trans Retinoic Acid and Paclitaxel for Enhanced Eradication of Osteosarcoma Stem Cells.ACS omega · 2026Article
- LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activation.Journal of experimental & clinical cancer research : CR · 2026Article
- Immune Infiltration Landscape in Osteosarcoma: Clinical Implications for Prognosis and Therapy.Cancer reports (Hoboken, N.J.) · 2026Article
- Rule-derived preoperative inflammatory-lymphocyte recovery phenotype and pathological response in resected osteosarcoma: a retrospective cohort study.Frontiers in immunology · 2026Article
- Clinical and tissue evidence of immune dysregulation in osteosarcoma: altered peripheral neutrophil-related indices and reduced APOE expression.Frontiers in immunology · 2026Article
- Immune exclusion as a recurrent immune-escape state driving treatment resistance in osteosarcoma: insights from single-cell, spatial, and multi-omics studies.Frontiers in immunology · 2026Review
- Extracellular Vesicles in Osteosarcoma: Mechanisms, Diagnostics and Therapeutic Applications.Drug design, development and therapy · 2026Review
- Metabolic-immune crosstalk in osteosarcoma: mechanisms and therapeutic opportunities.Frontiers in immunology · 2026Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is a primary malignant tumor that tends to threaten children and adolescents, and the 5-year event-free survival rate has not improved significantly in the past three decades, bringing grief and economic burden to patients and society. To date, the genetic background and oncogenesis mechanisms of osteosarcoma remain unclear, impeding further research. The tumor immune microenvironment has become a recent research hot spot, providing novel but valuable insight into tumor heterogeneity and multifaceted mechanisms of tumor progression and metastasis. However, the immune microenvironment in osteosarcoma has been vigorously discussed, and the landscape of immune and non-immune component infiltration has been intensively investigated. Here, we summarize the current knowledge of the classification, features, and functions of the main infiltrating cells, complement system, and exosomes in the osteosarcoma immune microenvironment. In each section, we also highlight the complex crosstalk network among them and the corresponding potential therapeutic strategies and clinical applications to deepen our understanding of osteosarcoma and provide a reference for imminent effective therapies with reduced adverse effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.